Search the Newsreel

Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis

Nektar Therapeutics (NKTR) has a current financial score of 6.40, placing it 254th out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently reported a quarterly revenue of $10.86 million, a 3.83% year-over-year …

Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Nektar Therapeutics (NKTR), highlighting its current valuation score of 7.54, which ranks 213 out of 386 in its industry. It details the company's current P/E ratio of -9.01, noting its position relative to recent highs and lows. …

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Nektar Therapeutics (NKTR) has initiated Phase 3 trials for rezpegaldesleukin in atopic dermatitis, a move that follows significant one-year stock growth but also a recent pullback. Despite a narrative suggesting a 54% undervaluation based on future revenue potential, its current P/S ratio signals high …

Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Nektar Therapeutics' (NKTR) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also includes institutional shareholding data over several quarters and recent shareholder activity, highlighting changes in holdings by various investment …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing by its officers and/or directors. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …

Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Nektar Therapeutics (NKTR), noting a lack of detailed financial disclosures for recent fiscal years. It indicates that all reported revenue, totaling $55.23 million, comes from the "Rest of world" region, with no disclosed revenue from the United …

How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials

Nektar Therapeutics has initiated global Phase 3 trials (ZENITH AD-1 and AD-2) for rezpegaldesleukin in moderate-to-severe atopic dermatitis, building on positive Phase 2b data and FDA Fast Track status. This move positions the T-reg–targeting biologic as a central focus for Nektar's autoimmune franchise but …

Nektar Therapeutics (NKTR) Institutional Confidence

The article provides an overview of Nektar Therapeutics' (NKTR) institutional confidence score, which stands at 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding proportion is 61.39%, a 16.36% decline quarter-over-quarter. James Simons is the largest institutional shareholder, with other major …

Nektar Therapeutics (NKTR) awards 16,500 stock options to Chief R&D Officer

Nektar Therapeutics has granted Chief R&D Officer Jonathan Zalevsky 16,500 stock options with an exercise price of $15.1500 per share, expiring December 12, 2032. These options, issued under the 2017 Amended and Restated Performance Incentive Plan, are subject to both performance-based and time-based vesting. …

Form 4 Nektar Therapeutics For: 24 July By Investing.com

This article reports on a Form 4 filing for Nektar Therapeutics (NKTR) on July 24, indicating insider transactions. The brief piece includes the stock's performance on the day and is framed within a typical financial news portal layout with various market data and related …

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics announced the grant of non-qualified stock options to 23 newly-hired employees under its 2025 Inducement Plan, as permitted by Nasdaq Listing Rule 5635(c)(4). These options cover 36,000 shares of common stock at an exercise price of $64.84, vesting over four years. The …

Nektar Therapeutics Initiated at Buy by Canaccord Genuity

Canaccord Genuity has initiated coverage on Nektar Therapeutics with a "Buy" rating. This indicates an optimistic outlook from the investment firm regarding the pharmaceutical company's future stock performance. Further details regarding specific price targets or reasons for the rating were not provided in this …

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Nektar Therapeutics (NKTR) announced the initiation of phase III clinical trials (ZENITH AD-1 and ZENITH AD-2) for its drug candidate, rezpegaldesleukin (rezpeg), to treat moderate-to-severe atopic dermatitis. The company's shares rose following the news, and rezpeg is also being developed for other autoimmune diseases …

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR) securities. The investigation focuses on whether Nektar and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before February 26, 2025, and still hold …

Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD

Nektar Therapeutics has launched its Phase 3 ZENITH AD program for rezpegaldesleukin, aimed at treating moderate-to-severe atopic dermatitis in patients aged 12 and older. The program includes three global trials, with ZENITH AD-1 and ZENITH AD-2 focusing on treatment-naive patients, and ZENITH AD-3 on …

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing. The firm is encouraging shareholders who purchased NKTR securities before February 26, 2025, and still hold them, to join their securities investigation. The firm operates on …

Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR

This article displays financial data for Nektar Therapeutics (BMV:NKTR), specifically its Enterprise Value to EBIT forward. It appears to be a financial snapshot from TradingView, showing the absence of trades and outlining the company's financial overview within the health technology and pharmaceutical sectors. The …

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run

Nektar Therapeutics (NKTR) has seen a significant 7x return over the last three years but is currently screening as overvalued according to Simply Wall St's analysis. The company's P/S ratio of 41.5x is considerably higher than the industry average and its estimated fair P/S …

Price to sales forward of Nektar Therapeutics – BMV:NKTR

This article provides financial information for Nektar Therapeutics (NKTR) on the Mexican Stock Exchange, focusing on its price-to-sales forward metric. It highlights that the market is closed with no recent trades. The content is primarily a data page from TradingView, offering an overview of …

ETFs Investing in Nektar Therapeutics Stocks

This article provides a comprehensive list of ETFs that hold Nektar Therapeutics (NKTR) stocks, detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs listed predominantly focus on small-cap, extended market, or healthcare sectors, …

A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility

Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153

Nektar Therapeutics Reports First Quarter 2026 Financial Results

Earnings call transcript: Nektar Therapeutics Q1 2026 reveals strong cash position amid mixed stock response

Nektar sets May 7 earnings release, webcast starts 5 p.m. ET

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up